CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Grant or award Director acquired 100,699 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Scientific Officer sold 63,606 shares at an average $28.25 ($1,796,676)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
- 4 Grant or award President and CEO acquired 160,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 62,500 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
- 4 Planned sale Chief Business Officer sold 40,000 shares at $16.18 ($647,200)
- 4 Planned sale Chief Business Officer sold 40,000 shares at $14.09 ($563,600)
- 4 Planned sale Chief Business Officer sold 40,000 shares at an average $12.31 ($492,508)
- 4 Open-market sale President and CEO sold 4,272 shares at $9.24 ($39,473)
- 4 Open-market sale Chief Medical Officer sold 1,860 shares at $8.50 ($15,810)
- 4 Open-market sale Chief Legal Officer sold 1,400 shares at $8.50 ($11,900)
- 4 Open-market sale Chief Financial Officer sold 1,920 shares at $8.50 ($16,320)
Page 5 of 13 · 253 filings